Skip to main content

Advertisement

SpringerLink
Log in

Oncolytic viruses get a boost with first FDA-approval recommendation

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

An Erratum to this article was published on 16 June 2015

This article has been updated

The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 16 June 2015

    In Table 1 of this article, the name of the oncolytic virus being developed by DNAtrix should have read 'DNX-2401'. This has been corrected in the online version of the article.

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 14, 369–371 (2015). https://doi.org/10.1038/nrd4643

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4643

  • Springer Nature Limited

This article is cited by

Search

Navigation